November 10, 2019 at 4:45 pm

Aptose Biosciences Inc. (NASDAQ:APTO) Shares Purchased by Sigma Planning Corp

by

Sigma Planning Corp raised its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 4.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 228,150 shares of the biotechnology company’s stock after acquiring an additional 9,000 shares during the period. Sigma Planning Corp’s holdings in Aptose Biosciences were worth $476,000 at the end of the most recent quarter.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several other institutional investors also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new position in shares of Aptose Biosciences in the 2nd quarter valued at about $5,742,000. Man Group plc purchased a new position in shares of Aptose Biosciences in the 2nd quarter valued at about $3,867,000. DRW Securities LLC increased its holdings in Aptose Biosciences by 30.8% during the 2nd quarter. DRW Securities LLC now owns 3,347,018 shares of the biotechnology company’s stock valued at $8,736,000 after acquiring an additional 788,560 shares in the last quarter. P.A.W. Capital Corp purchased a new position in Aptose Biosciences during the 3rd quarter valued at about $1,043,000. Finally, Sanders Morris Harris LLC purchased a new position in Aptose Biosciences during the 2nd quarter valued at about $572,000. 21.53% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have issued reports on APTO. Zacks Investment Research cut shares of Aptose Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, August 12th. ValuEngine cut shares of Aptose Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, October 10th. Finally, HC Wainwright decreased their price target on shares of Aptose Biosciences from $8.50 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $5.25.

Shares of APTO traded up $0.01 during mid-day trading on Friday, hitting $2.37. The company had a trading volume of 152,100 shares, compared to its average volume of 310,342. The stock has a market cap of $127.53 million, a PE ratio of -2.76 and a beta of 1.64. The business’s 50-day simple moving average is $2.12 and its 200-day simple moving average is $2.28. Aptose Biosciences Inc. has a 1-year low of $1.57 and a 1-year high of $3.13. The company has a quick ratio of 11.27, a current ratio of 11.27 and a debt-to-equity ratio of 0.04.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. On average, sell-side analysts expect that Aptose Biosciences Inc. will post -0.59 earnings per share for the current year.

Aptose Biosciences Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Further Reading: Options Trading

Want to see what other hedge funds are holding APTO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS).

Institutional Ownership by Quarter for Aptose Biosciences (NASDAQ:APTO)

Leave a Comment

Your email address will not be published. Required fields are marked *